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Purpose or Objective: PROS-IT is a national, multicenter, 
observational prospective cohort study on prostate cancer 
(PCa) coordinated by the Italian National Research Council, 
aiming at a comprehensive evaluation of the impact of PCa 
and its treatment in an unselected aging population. Present 
analysis evaluates the frequencies of the different 
comorbidities and medications in the study population at 
diagnosis. 
 
Materials and Methods: 1684 patients (pts) consecutively 
enrolled 9/2014 to 7/2015 in 96 Institutions were submitted 
to a structured interview to record comorbidities and drugs 
assumption. The severity of comorbidities was measured with 
the Cumulative Illness Rating Scale (CIRS). Quality of life 
(QoL) was assessed by the SF-12 questionnaire (PCS = Physical 
and MCS = Mental Component Summary) and through the 
Italian UCLA P Ca Index (Function/Bother: UF,UB=Urinary , 
SF,SB=Sexual , BF,BB=Bowel ). Differences between pts 
enrolled by Urology [URO] and Radiation Oncology Centers 
[RO] were assessed with logistic regression and/or general 
linear models. 
 
Results: 996/1684 (59.1%) and 688/1684 (40.9%) pts were 
respectively enrolled by URO and RO Centers; CIRS data were 
available for 1637 pts. RO pts were older (average 71.9 yrs vs 
66.4, p<0.0001), with more advanced T category (T1 cases: 
38% vs 54.6%, p<0.0001). 445/1684 (27.2%) pts suffered from 
vascular, lymphatic or hematopoietic moderate, severe or 
very severe (MSVS) diseases; 304/1684 (18.6%) from heart 
MSVS disease; 231/1684 (14.2%) had gastro-intestinal 
problems; 163/1684 (10%) neurological diseases. The 
presence of ≥3 MSVS comorbidities had a significant negative 
impact on PCS, MCS, UB, BF and BB, SF if compared to 0-2 
MVSV comorbidities (p<0.001).Diabetes was more frequent in 
RO pts than in URO ones (18.4% vs.11.4%, p=0.0082); MSVS 
gastrointestinal disease (18.8% vs. 7.5%), abdominal hernia 
(5.7% vs. 4.8%), and neurological disease (11.4% vs. 7.9%) in 
URO pts. 74.3% of the pts use drugs for vascular disease, 
36.7% antithrombotic agents, 34.2% digestive drugs, 14.4% 
hypoglycemic drugs, 31.6% drugs for low urinary tract 
symptoms. A significant difference between URO and RO 
populations in the use of antithrombotic agents was evident: 
32.5% URO vs. 44% RO (p=0.0377). 
 
Conclusion: This study shows that number and severity of 
comorbidities had a negative impact on QoL at the time of 
diagnosis of PCa. Moreover, men enrolled in URO and RO 
Centers present a different pattern of associated 
diseases/medications.  
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Purpose or Objective: Contact X Ray Brachytherapy (CXB) 
was pioneered in France for conservative treatment of rectal 
cancer using the Philips RT 50TM machine. Since 2009 the 
new Papillon 50TM was manufactured. It delivers high dose 
rate (20 Gy/ mn) well targeted dose (30 Gy) into the rectal 
tumor using an endoscopic approach. For T2 T3 CXB is always 
combined with external beam Radiotherapy(EBRT) or with 
chemoraradiotherapy (CRT). Three centers have been 
treating patients in France with such regimen in Lyon-
Villeurbanne, Mâcon and Nice. 
 
Material and Methods: All patients presented 
adenocarcinoma of the distal or middle rectum. Staging used 
Digital examination, endoscopy, MRI and or Endorectal 
ultrasound. CXB dose was 90Gy in 3 fractions (Day 1- 14 -28) 
and EBRT delivered 50 Gy/25 fr/5 weeks usually with 
concurrent capecitabine (800 mg/m2 BID). After clinical 
complete response (cCR) either watch and Wait (W§W) or 
Local excision (LE) was proposed. 
 
Results: Between 2009 and 2014, 44 patients were treated. 
All these patients were either high surgical risk, refusal of 
surgery or referred after MDT approval for such a 
conservative approach Results are shown in Table . 
 
Centre N° pts T2 T3 cCR Loc. Rec. Organ Preserv Surv. 3 years 
Mâcon 14 6 8 10 3 9 75% 
Nice 22 13 9 20 2 21 70% 
Villeurbanne 8 6 2 8 1 7 87% 
Total 44 25 19 89% (38) 13% (6) 83% (37) 77% 
 
Conclusion: The present early results achieved with the 
Papillon 50 machine are at least equivalent to the previous 
one using Philips RT 50. CXB technique is validated in France 
for rectal cancer since 2008 (HAS) and recently in UK (NICE). 
Organ preservation using CXB in frail, elderly patients is a 
well admitted treatment and the ongoing OPERA trial is 
aiming at showing its benefit in operable patients. Gerard JP 
et al. Acta Oncol. 2015 Apr;54(4):545-51. 
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Purpose or Objective: TME surgery, with or without pre-
operative (chemo-)radiotherapy is the standard of care in 
patients with resectable rectal cancer. In patients unfit for 
surgery, radiotherapy alone is often used with palliative 
intent. However, complete response can be achieved when 
high doses are administered. In this study we examined the 
feasibility of external beam radiotherapy (EBRT) followed by 
an endorectal brachytherapy boost in elderly patients, unfit 
for surgery. Primary results, presented at ESTRO 2014, are 
now complemented with response assessment and long-term 
FU at 3 years. 
 
Material and Methods: A dose finding feasibility study was 
performed from 2007 to 2013 in two hospitals in inoperable 
rectal cancer patients. Treatment consisted of EBRT (13x3 
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Gy) followed by 3 weekly applications of intraluminal high 
dose rate brachytherapy (HDRBT)starting 6 weeks after EBRT. 
The starting dose level was 3x5 Gy with escalation of 1 Gy 
per fraction if acute toxicity was acceptable. Toxicity was 
acceptable if <2/6 patients or <3/9 patients exhibited dose 
limiting toxicity (DLT), defined as grade 3 proctitis (CTCAE v 
3.0), within 6 weeks after HDRBT. Secondary endpoints were 
severe treatment-related late toxicity, clinical tumor 
response and progression free survival (PFS). Clinical tumor 
response was evaluated based on all available endoscopy 
pictures and defined as complete clinical response (CR), 
partial response (PR), stable disease (SD) or progression (PD). 
 
Results: Thirty-eight patients with a mean age of 81 years, 
entered the study of whom 36 received HDRBT. Two patients 
died directly after HDRBT and 3 patients refused follow-up 
endoscopies, leaving 31 patients for response evaluation. At 
time of current analyses 13 patients were still alive, with a 
median FU of 30 months. Primary endpoint was reached at 
the 8 Gy dose-level with 3/9 patients showing a DLT. 
Response was observed in 25 patients (80.6%); of the 18 
patients achieving a CR, 6 developed progressive disease 
later on. Of the 7 patients with PR, 4 showed progression, 
whereas this occurred in 5/6 patients with SD. Median time 
to progression was 6.3 months. PFS at 1,2 and 3 years was 
65.6%, 46.4% and 22.1% respectively. Late treatment related 
grade 3/4 toxicity occurred in 13 patients, of those 9 patients 
also showed progressive disease. Outcomes related to 
doselevel are displayed in table 1. 
 
 
Conclusion: A combination of EBRT and HDRBT is feasible in 
inoperable elderly patients with acceptable acute toxicity 
and a promising overall response rate of 80.6%. However, 
given the observed toxicity, a randomized trial comparing 
EBRT with or without HDRBT boost is necessary. In this trial 
the clinical relevance of the added tumor control in light of 
additional toxicity from HDRBT will be evaluated in this 
fragile population. 
 
OC-0149  
Patterns of relapse in rectal cancer patients following pre-
operative high dose rate brachytherapy 
T. Vuong
1Jewish General Hospital, Radiation Oncology, Montreal, 
Canada 
1, F. Desjardins2, V. Pelsser3, T. Niazi1, A. Robillard2, 
M. Leventhal3 
2Centre Hospitalier Pierre-Boucher, Radiology, Longueuil, 
Canada 
3Jewish General Hospital, Radiology, Montreal, Canada 
 
Purpose or Objective: Radiation therapy is an established 
neoadjuvant modality for patients with advanced rectal 
cancer. As the quality of surgery improved with Total 
Mesorectal Excision surgery (TME), radiation is now being 
challenged, as the number of patients needed to treat 
remains high when facing long-term normal tissue toxicity in 
the pelvis. High dose rate endorectal brachytherapy is a 
highly targeted form of radiation based on quality imaging 
with magnetic resonant imaging and was introduced in our 
institution along with TME. Unlike external beam radiation 
therapy, the clinical target volume is aiming mostly at the 
tumor bed. We are reporting the patterns of relapse of our 
patients after 15 years experience. 
 
Material and Methods: Patients with operable rectal cancer 
based on pelvic MRI staging, are considered at risk for local 
recurrence were included; for physical reasons, those with 
obstructive tumors and positive extramesorectal nodes were 
excluded. Patients received treatment with 26 Gy in 4 
fractions using a remote afterloader with an endoluminal 
cylindrical multichannel applicator and an Iridium 192 
source. The CTV is defined as the gross tumor volume 
observed on the diagnostic MRI with no attempt to cover the 
perirectal nodes. 667 patients treated from 1999-2015, most 
of which were T3 tumors (84%), low T2 (13%) and early T4 
(3%); 36 % of the patients had positive nodes on pre-operative 
imaging. The local failure in our patient population is 4.7 % 
with a median follow up time of 65 months for 608 patients 
(range 6-165 months). Twenty-eight patients had pelvic 
recurrence, of which 25 were documented with MRI and 3 
were found with CT scan. The Imaging was reviewed by two 
radiologists. 
 
Results: The location of recurrence were identified as: iliac 
or lateral nodes in 11 patients, anastomotic in 10 patients, 
inguinal nodes in 3 patients, anterior compartment in 4 
patients and pre-sacral space in one patient (one patient had 
more than 2 sites). In the patients with nodal pelvic relapses, 
the relapse was isolated for 3 patients and in the other 8 
patients there were associated systemic relapses, and these 
patients were asymptomatic and did not require pelvic 
radiation while the former 3 patients underwent successful 
salvage radiation with IMRT (1) /SBRT for 2 patients. Another 
9 patients with isolated pelvic relapses received pre-
operative pelvic radiation with salvage surgery. 
 
Conclusion: In patients with rectal cancer treated with pre-
operative HDRBT, pelvic nodal relapse was the most common 
site of recurrence and was often associated with 
asymptomatic systemic relapse. Those patients with isolated 
nodal relapse are salvageable with either IMRT of SBRT. For 
patients with localized recurrence, pre-operative pelvic 
radiation was possible with salvage surgery. Pre sacral 
recurrence is a rare event, with a single patient observed. 
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Purpose or Objective: Locally advanced unresectable biliary 
carcinoma often present as extrahepatic malignant biliary 
obstruction with jaundice. The aim of treatment is to relieve 
jaundice and pruritus either by endoscopic biliary drainage 
(EBD) or percutaneous transhepatic biliary drainage (PTBD) 
followed by stenting. Stent is frequently blocked due to 
either tumour ingrowth or overgrowth. Intraluminal 
brachytherapy (ILBT) allows high dose to of radiation to local 
tumor area and delays the stent block. The purpose of this 
study is to assess the safety and efficacy of ILBT and impact 
of external beam radiotherapy(EBRT) on stent patency and 
survival. 
 
Material and Methods: From 1998-2008, 172 unresectable, 
locally advanced biliary cancers (pancreas-12, gallbladder-
140, cholangiocarcinoma-20), presenting with malignant 
extrahepatic biliary obstruction were prospectively treated 
with PTBD and stenting followed by ILBT with or without 
EBRT. The 110/172(64%) patients received ILBT alone (ILBT 
group) while 62/172(36%) received ILBT followed by 
EBRT(EBRT group). Endoscopic retrograde cholangio 
pancreaticography (ERCP) and/or percutaneous 
cholangiogram (PC) was done in all. Biliary drainage was done 
by standard ultrasound and fluoroscopy guided percutaneous 
transhepatic puncture. The stricture was dilated by balloon 
catheter over the guide wire. The biliary tract was dilated 
repeatedly and upsized till 12 French Malecot catheter. High 
